Posted by Michael Wonder on 17 May 2022
United Kingdom MHRA grants marketing authorisation for FYB201, Formycon's biosimilar for Lucentis
17 May 2022 - Formycon and its license partner Bioeq announce that today the MHRA has granted marketing authorisation in the United Kingdom for FYB201, a biosimilar to Lucentis (ranibizumab).
Teva Pharmaceutical Industries will serve as the exclusive commercial partner and will market the biosimilar under the brand name Ongavia throughout the UK.
The MHRA approval is based on a totality of evidence including analytical, clinical and manufacturing data.
